Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Lei Duan and Carl Maki.
Lei Duan
Connection Strength
14.309
Carl Maki
  1. Determinants of Aurora kinase B inhibitor sensitivity in small cell lung cancer. Transl Lung Cancer Res. 2024 Feb 29; 13(2):223-228.
    View in: PubMed
    Score: 0.944
  2. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271.
    View in: PubMed
    Score: 0.918
  3. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75.
    View in: PubMed
    Score: 0.872
  4. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10.
    View in: PubMed
    Score: 0.872
  5. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525.
    View in: PubMed
    Score: 0.825
  6. Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jan 31; 14(3).
    View in: PubMed
    Score: 0.819
  7. Corrigendum to 'Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells'. J Mol Cell Biol. 2022 Jan 29; 13(12):922.
    View in: PubMed
    Score: 0.818
  8. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049.
    View in: PubMed
    Score: 0.817
  9. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444.
    View in: PubMed
    Score: 0.797
  10. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197.
    View in: PubMed
    Score: 0.676
  11. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657.
    View in: PubMed
    Score: 0.673
  12. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260.
    View in: PubMed
    Score: 0.650
  13. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340.
    View in: PubMed
    Score: 0.642
  14. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675.
    View in: PubMed
    Score: 0.572
  15. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56.
    View in: PubMed
    Score: 0.526
  16. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300.
    View in: PubMed
    Score: 0.486
  17. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705.
    View in: PubMed
    Score: 0.482
  18. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12.
    View in: PubMed
    Score: 0.467
  19. Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Transl Oncol. 2022 May; 19:101386.
    View in: PubMed
    Score: 0.206
  20. Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903.
    View in: PubMed
    Score: 0.200
  21. P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95.
    View in: PubMed
    Score: 0.193
  22. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040.
    View in: PubMed
    Score: 0.187
  23. DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a. Cancer Biol Ther. 2018 06 03; 19(6):465-474.
    View in: PubMed
    Score: 0.156
  24. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903.
    View in: PubMed
    Score: 0.149
  25. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26.
    View in: PubMed
    Score: 0.138
  26. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47.
    View in: PubMed
    Score: 0.136
  27. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119.
    View in: PubMed
    Score: 0.053
  28. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
    View in: PubMed
    Score: 0.034
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.